Bernar, Benoît
Gande, Nina
Stock, Anna Katharina
Staudt, Anna
Pechlaner, Raimund
Hochmayr, Christoph
Kaltseis, Katharina
Winder, Bernhard
Kiechl, Sophia Julia J.
Broessner, Gregor
Geiger, Ralf
Kiechl, Stefan
Anliker, Markus
Asare, Mandy
Bock-Bartl, Manuela
Bohl, Maximilian
Griesmacher, Andrea
Klingenschmid, Julia
Kothmayer, Martina
Marxer, Julia
Pircher, Maximilian
Reiter, Carmen
Schreiner, Christina
Kiechl-Kohlendorfer, Ursula
Knoflach, Michael
,
Funding for this research was provided by:
Österreichische Forschungsförderungsgesellschaft
Article History
Received: 26 March 2023
Accepted: 19 July 2023
First Online: 1 August 2023
Declarations
:
: The consent-form, as well as the complete EVA-Tyrol-Study protocol, has been approved by the local ethics-committee Innsbruck (AN2015–0005 345/4.13). The study was conducted according to the guidelines of good clinical practice (GCP) and the declaration of Helsinki.Informed consent was approved and signed by all participants and additionally, if the participants were aged under 18 years, by the legal representative (parents/guardians).
: Not applicable.
: Benoît Bernar – Disclosure none –Nina Gande – Disclosure none –Anna Katharina Stock – Disclosure none –Anna Staudt – Disclosure none –Raimund Pechlaner – Disclosure none –Christoph Hochmayr – Disclosure none –Katharina Kaltseis – Disclosure none –Bernhard Winder – Disclosure none –Sophia Julia Kiechl – Disclosure none –Gregor Broessner has recieved unrestricted grants, honoraria, personal fees, and travel grants from: Allergan, AMGEN, Menarini, Pfizer, Linde AG, Astra Zeneca, St. Jude Medical, Reckitt Benkiser, Novartis, TEVA, Fresenius, Janssen Cilag, and Lilly.Ralf Geiger – Disclosure none –Stefan Kiechl – Disclosure none –Ursula Kiechl-Kohlendorfer – Disclosure none –Michael Knoflach has received honoraria and personal fees from Pfizer and Novartis.